🎙️ POST ESMO 2025 – Advances in Hepatic, Pancreatic, and Neuroendocrine Tumors New evidence, emerging concepts, and future perspectives in hepatobiliopancreatic malignancies following ESMO 2025. In this episode, Dr. Ángela Lamarca reviews the most relevant results in hepatocellular carcinoma, biliary tract cancers, pancreatic adenocarcinoma, and neuroendocrine tumors, highlighting studies with the greatest clinical and conceptual impact. In hepatocellular carcinoma, the SKYSCRAPER-14 trial reports data on the use of atezolizumab–bevacizumab with or without tiragolumab, showing no additional benefit from tiragolumab. The CARES-009 study introduces a perioperative approach combining camrelizumab and rivoceranib, demonstrating improved event-free survival in resectable disease. The ABC-HCC and TALENTop trials further reinforce the role of atezolizumab and bevacizumab in intermediate stages and in patients achieving a systemic response prior to surgery. In biliary tract cancers, four trials in FGFR2-positive patients treated with tinengotinib show meaningful data on progression-free survival, including in those previously exposed to FGFR inhibitors. The FIRST-308 trial randomizes patients who progressed after prior FGFR inhibition to receive tinengotinib versus chemotherapy. In pancreatic adenocarcinoma, KRAS G12D inhibitors emerge as a promising approach, with the GFH-375 (monotherapy) and HRS4642 (in combination with chemotherapy plus gemcitabine and nab-paclitaxel) trials reporting response rates between 20% and 40.7%. Other innovative strategies include the VCN01 vaccine combined with gemcitabine plus nab-paclitaxel, and Temab-A, an anti-c-Met antibody–drug conjugate, achieving an overall response rate (ORR) of 23.2% in previously treated patients. In neuroendocrine tumors, the observational ASPEN study evaluates small non-functioning pancreatic lesions, showing tumor growth rates of 7.5% and 18.5% at 2 and 7 years, respectively, and a surgical intervention rate of 2.2% and 18.5% over the same periods. Among patients previously treated with alpha-emitting radionuclides, ALPHAMEDIX-02 reports an ORR of 34.6% and a disease control rate of 96.2%, with some adverse events not observed in earlier studies. Finally, in neuroendocrine and pancreatic neuroendocrine tumors, LITSPARK-015 with oral belzutifan demonstrates favorable response and disease control rates. This edition reflects the dynamism of gastrointestinal oncology: trials that challenge the standard of care, novel molecular targets, and increasingly precise, patient-tailored treatment strategies. --------------------------------------------------------------------------------------------------- 🎧 Listen now at https://transworldeditors.com/toomore-gi-2 This podcast aims to provide continuing medical education and inform healthcare professionals. It is not a substitute for professional medical care and is not intended for the diagnosis or treatment of specific cases. The participants express their own opinions, experiences, and conclusions.